Your browser doesn't support javascript.
loading
Disulfiram Treatment Normalizes Body Weight in Obese Mice.
Bernier, Michel; Mitchell, Sarah J; Wahl, Devin; Diaz, Antonio; Singh, Abhishek; Seo, Wonhyo; Wang, Mingy; Ali, Ahmed; Kaiser, Tamzin; Price, Nathan L; Aon, Miguel A; Kim, Eun-Young; Petr, Michael A; Cai, Huan; Warren, Alessa; Di Germanio, Clara; Di Francesco, Andrea; Fishbein, Ken; Guiterrez, Vince; Harney, Dylan; Koay, Yen Chin; Mach, John; Enamorado, Ignacio Navas; Pulpitel, Tamara; Wang, Yushi; Zhang, Jing; Zhang, Li; Spencer, Richard G; Becker, Kevin G; Egan, Josephine M; Lakatta, Edward G; O'Sullivan, John; Larance, Mark; LeCouteur, David G; Cogger, Victoria C; Gao, Bin; Fernandez-Hernando, Carlos; Cuervo, Ana Maria; de Cabo, Rafael.
Afiliación
  • Bernier M; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA. Electronic address: bernierm@mail.nih.gov.
  • Mitchell SJ; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Wahl D; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord
  • Diaz A; Department of Developmental and Molecular Biology, Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.
  • Singh A; Vascular Biology and Therapeutics Program, Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Seo W; Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA.
  • Wang M; Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Ali A; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Kaiser T; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Price NL; Vascular Biology and Therapeutics Program, Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Aon MA; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Kim EY; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA; Functional Genomics Research Center, KRIBB, Daejeon 305-806, Republic of Korea.
  • Petr MA; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Cai H; Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Warren A; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
  • Di Germanio C; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Di Francesco A; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Fishbein K; Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Guiterrez V; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Harney D; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
  • Koay YC; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Heart Research Institute, The University of Sydney, Sydney, NSW 2042, Australia.
  • Mach J; Kolling Institute of Medical Research and Sydney Medical School, University of Sydney, Sydney, NSW 2065, Australia.
  • Enamorado IN; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • Pulpitel T; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
  • Wang Y; Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Zhang J; Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Zhang L; Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Spencer RG; Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Becker KG; Laboratory of Genetics, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Egan JM; Laboratory of Clinical Investigation, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • Lakatta EG; Laboratory of Cardiovascular Science, Intramural Research Program, National Institute on Aging, NIH, Baltimore, MD 21224, USA.
  • O'Sullivan J; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Heart Research Institute, The University of Sydney, Sydney, NSW 2042, Australia.
  • Larance M; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia.
  • LeCouteur DG; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
  • Cogger VC; Charles Perkins Centre, The University of Sydney, Sydney, NSW 2006, Australia; Ageing and Alzheimer's Institute, ANZAC Research Institute, Concord Clinical School/Sydney Medical School, Concord, NSW 2139, Australia.
  • Gao B; Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD 20892, USA.
  • Fernandez-Hernando C; Vascular Biology and Therapeutics Program, Integrative Cell Signaling and Neurobiology of Metabolism Program, Department of Comparative Medicine, Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA.
  • Cuervo AM; Department of Developmental and Molecular Biology, Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY 10461, USA.
  • de Cabo R; Experimental Gerontology Section, Translational Gerontology Branch, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA. Electronic address: decaboRa@mail.nih.gov.
Cell Metab ; 32(2): 203-214.e4, 2020 08 04.
Article en En | MEDLINE | ID: mdl-32413333
ABSTRACT
Obesity is a top public health concern, and a molecule that safely treats obesity is urgently needed. Disulfiram (known commercially as Antabuse), an FDA-approved treatment for chronic alcohol addiction, exhibits anti-inflammatory properties and helps protect against certain types of cancer. Here, we show that in mice disulfiram treatment prevented body weight gain and abrogated the adverse impact of an obesogenic diet on insulin responsiveness while mitigating liver steatosis and pancreatic islet hypertrophy. Additionally, disulfiram treatment reversed established diet-induced obesity and metabolic dysfunctions in middle-aged mice. Reductions in feeding efficiency and increases in energy expenditure were associated with body weight regulation in response to long-term disulfiram treatment. Loss of fat tissue and an increase in liver fenestrations were also observed in rats on disulfiram. Given the potent anti-obesogenic effects in rodents, repurposing disulfiram in the clinic could represent a new strategy to treat obesity and its metabolic comorbidities.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Peso Corporal / Fármacos Antiobesidad / Disulfiram / Obesidad Idioma: En Revista: Cell Metab Asunto de la revista: METABOLISMO Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Peso Corporal / Fármacos Antiobesidad / Disulfiram / Obesidad Idioma: En Revista: Cell Metab Asunto de la revista: METABOLISMO Año: 2020 Tipo del documento: Article